Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”
Publication date
2026-01
Authors
Clabbers, Julia
Boesjes, Celeste
van Geel, Michel
de Bruin-Weller, Marjolein
Gostynski, Antoni
Editors
Advisors
Supervisors
Document Type
Letter
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
atopic dermatitis, biologics, dupilumab, filaggrin, skin barrier, Taverne, Dermatology
Citation
Clabbers, J, Boesjes, C, van Geel, M, de Bruin-Weller, M & Gostynski, A 2026, 'Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype : Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”', Journal of the American Academy of Dermatology, vol. 94, no. 1, pp. e43-e44. https://doi.org/10.1016/j.jaad.2025.06.083